Rational Pharmacotherapy in Cardiology

Advanced search

Renal Function Protection as an Important Component of a Comprehensive Approach to the Management of Patients with Atrial Fibrillation

Full Text:


The increase in the life expectancy of the population  is accompanied by an increase in the prevalence of diseases for which old and senile age are risk factors. Atrial fibrillation (AF) and chronic kidney disease (CKD) are two diseases that can coexist in a patient. The risk of ac thromboembolic and hemorrhagic events in this case increases due to the mutual aggravating influence of these diseases. In addition,  these patients have a high incidence of coronary  events, and cardiovascular complications are the main cause of death in patients with AF and CKD. Consequently, such patients require an integrated  approach  to treatment,  and their management is a complex  clinical task. The direct oral anticoagulant rivaroxaban has been most studied in a population  of comorbid  AF and CKD  patients and has proven a high efficacy and safety profile in these patients in randomized controlled trials. In addition,  rivaroxaban has shown  a significant  reduction in the risk of myocardial  infarction  in various patients,  as well as the possibility of preserving renal function to a greater extent compared  with warfarin therapy, and a possible positive effect on reducing  the risk of cognitive impairment.  A single dosing  regimen  can improve adherence  to treatment,  which is one of the key conditions  for achieving  the above effects. Thus, these factors make it possible to achieve comprehensive protection of comorbid  patients with AF and CKD.

About the Author

T. V. Pavlova
Samara State Medical University
Russian Federation

Tatyana V. Pavlova.



1. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease — a systematic review and meta-analysis. PLoS ONE. 2016;11(7):e0158765. DOI:10.1371/journal.pone.015876.

2. Boytsov SA, Loukianov MM, Yakushin SS, et al. Cardiovascular diseases registry (RECVAZA): diagnostics, concomitant cardiovascular pathology, comorbidities and treatment in the real outpatient-polyclinic practice. Cardiovascular Therapy and Prevention. 2014;13(6):44-50 (In Russ.) DOI:10.15829/1728-8800-2014-6-44-50.

3. Chashkina MI, Kozlovskaya NL, Andreev DA, et al. Prevalence of Advanced Chronic Kidney Disease in Patients with Nonvalvular Atrial Fibrillation Hospitalized in Cardiology Departments. Kardiologiia.

4. 2020;60(2):41-6 (In Russ.) DOI:10.18087/cardio.2020.2.n823.

5. Thompson S, James M, Wiebe N, et al., for the Alberta Kidney Disease Network. Cause of Death in Patients with Reduced Kidney Function. J Am Soc Nephrol. 2015;26(10):2504-11. DOI:10.1681/ASN.2014070714.

6. Bansal N, Fan D, Hsu CY, et al. Incident Atrial Fibrillation and Risk of Death in Adults With Chronic Kidney Disease. J Am Heart Assoc. 2014;3(5):e001303. DOI:10.1161/jaha.114.001303.

7. Carrero JJ, Trevisan M, Sood MM, et al. Incident Atrial Fibrillation and the Risk of Stroke in Adults with Chronic Kidney Disease: The Stockholm CREAtinine Measurements (SCREAM) Project. Clin J Am Soc Nephrol. 2018;13(9):1314-20. DOI:10.2215/CJN.04060318.

8. Olesen JB, Lip GYH, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367(7):625-35. DOI:10.1056/NEJMoa1105594.

9. Bansal N, Xie D, Sha D, et al. Cardiovascular Events after New-Onset Atrial Fibrillation in Adults with CKD: Results from the Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol. 2018;29(12):2859-69. DOI:10.1681/ASN.2018050514.

10. Tapoi L, Ureche C, Sascau R, et al. Atrial fbrillation and chronic kidney disease conundrum: an update. J Nephrol. 2019;32(6):909-17. DOI:10.1007/s40620-019-00630-1.

11. Vizir VA, Berezin AE. Cardiorenal syndrome. Arterial Hypertension. 2011;16(2):24-9 (In Russ.)

12. Garcia-Donaire A, Ruilope LM. Cardiovascular and Renal Links along the Cardiorenal Continuum. Int J Nephrol. 2011;2011:975782. DOI:10.4061/2011/975782.

13. Hatamizadeh P, Fonarow GC, Budoff MJ, et al. Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol. 2013;9(2):99-111. DOI:10.1038/nrneph.2012.279.

14. Bassand JP, Accetta G, Al Mahmeed W, et al. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS One. 2018;13(1):e0191592. DOI:10.1371/journal.pone.0191592.

15. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-76. DOI:10.1093/europace/euab065.

16. Wilke T, Bauer S, Mueller S, et el. Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review. Patient. 2017;10(1):17-37. DOI:10.1007/s40271-016-0185-9.

17. Reshetko OV, Sokolov AV, Furman NV. Analysis of antithrombotic therapy for atrial fibrillation in international and Russian registries. Good Clinical Practice. 2019;(1):83-96 (In Russ.) DOI:10.24411/2588-0519-2019-10066.

18. Ozaki AF, Choi AS, Le QT, et el. Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes. 2020;13(3):e005969. DOI:10.1161/CIRCOUTCOMES.119.005969.

19. Efimova OI, Sergeeva MA, Pavlova TV, et al. A patient with cardioembolic stroke: characteristics and features. Fundamental and Clinical Medicine. 2020;5(2):30-8 (In Russ.) DOI:10.23946/2500-0764-2020-5-2-30-38.

20. Instructions for use of the medicinal product for medical use of the medicinal product Pradaxa [cited 2021 Oct 10]. Available from: (In Russ.) Доступно на:

21. Instructions for use of the medicinal product for medical use of the medicinal product Xarelto [cited 2021 Oct 10]. Available from: Instructions for use of the medicinal product for medical use of the medicinal product Eliquis (In Russ.)

22. Instructions for use of the medicinal product for medical use of the medicinal product Eliquis [cited 2021 Oct 10]. Available from: (In Russ.) Доступно на:

23. Instructions for use of the medicinal product for medical use of the medicinal product Warfarin [cited 2021 Oct 10]. Available from: dd70e50d-f9aa-42c8-be0b-44d6562a0994&t= (In Russ.) Доступно на:

24. Pankratov YV, Pigarova EA, Dzeranova L.K. Vitamin K-dependent proteins: osteocalcin, the Gla-protein matrix and vnekostnye effects. Ozhirenie I Metabolizm 2013;(2):11-8 (In Russ.)

25. Han KH, O'Neill WC. Increased Peripheral Arterial Calcification in Patients Receiving Warfarin. J Am Heart Assoc. 2016;5(1):e002665. DOI:10.1161/JAHA.115.002665.

26. Weijs B, Blaauw Y, Rennenberg RJ, et al. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J. 2011;32(20):2555-62. DOI:10.1093/eurheartj/ehr226.

27. Dahal K, Kunwar S, Rijal J, et al. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease. Chest. 2016;149(4):951-9. DOI:10.1378/chest.15-1719.

28. Weir MR, Berger JS, Ashton V, et al. Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence. Curr Med Res Opin. 2017;33(10):1891-900. DOI:10.1080/03007995.2017.1339674.

29. Jain N, Reilly RF. Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease. Clin J Am Soc Nephrol. 2019;14(2):278-87. DOI:10.2215/CJN.02170218.

30. Brodsky SV, Satoskar A, Chen J, et al. Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. Am J Kidney Dis. 2009;54(6):1121-6. DOI:10.1053/j.ajkd.2009.04.024.

31. Wheeler DS, Giugliano RP, Rangaswami J. Anticoagulation related nephropathy. J Thromb Haemost. 2016;14(3):461-7. DOI:10.1111/jth.13229.

32. Brodsky SV, Nadasdy T, Rovin BH, et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int. 2011;80(2):181-9. DOI:10.1038/ki.2011.44.

33. Hindricks G, Potpara T, Dagres N, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. DOI:10.1093/eurheartj/ehaa612.

34. Steinberg BA, Shrader P, Thomas L, et al. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J. 2017;189:40-7. DOI:10.1016/j.ahj.2017.03.024.

35. Gu ZC, Kong LC, Yang SF, et al. Net clinical benefit of non-vitamin K antagonist oral anticoagulants in atrial fibrillation and chronic kidney disease: a trade-off analysis from four phase III clinical trials. Cardiovasc Diagn Ther. 2019;9(5):410-9. DOI:10.21037/cdt.2019.07.09.

36. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. DOI:10.1056/NEJMoa1009638.

37. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387-94. DOI:10.1093/eurheartj/ehr342.

38. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. DOI:10.1056/NEJMoa0905561.

39. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2010;70(5):703-12. DOI:10.1111/j.1365-2125.2010.03753.x.

40. Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol. 2012;26(1):27-32. DOI:10.1111/j.1472-8206.2011.00981.x.

41. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. DOI:10.1056/NEJMoa1107039.

42. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821-30. DOI:10.1093/eurheartj/ehs274.

43. Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014;129(9):961-70. DOI:10.1161/CIRCULATIONAHA.113.003628.

44. Hu L, Xiong Q, Chen Z, Fu L, et al. Factors Associated with a Large Decline in Renal Function or Progression to Renal Insufficiency in Hospitalized Atrial Fibrillation Patients with Early-Stage CKD. Int Heart J. 2020;61(2):239-48. DOI:10.1536/ihj.19-205.

45. Cockcroft DW, Gault H. Prediction of Creatinine Clearance from Serum Creatinine. Nephron. 1976;16(1):31-41. DOI:10.1159/000180580.

46. Hijazi Z, Granger CB, Hohnloser SH, et al. Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation. J Am Heart Assoc. 2020;9(18):e017155. DOI:10.1161/JAHA.120.017155.

47. Fedorova DN, Lazarev PV. The role of various methods of kidney function assessment in dosing of oral anticoagulants in atrial fibrillation patients. Clin Pharmacol Ther. 2019;28(3):21-4 (In Russ.) DOI:10.32756/0869-5490-2019-3-21-24.

48. Nielsen PB, Skjøth F, Søgaard M, et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510. DOI:10.1136/bmj.j510.

49. Yao X, Shah ND, Sangaralingham LR, et al. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol. 2017;69(23):2779-90. DOI:10.1016/j.jacc.2017.03.600.

50. Hawkins NM, Jhund PS, Pozzi A, et al. Severity of renal impairment in patients with heart failure and atrial fbrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. Eur J Heart Fail. 2016;18(9):1162-71. DOI:10.1002/ejhf.614.

51. Yao X, Tangri N, Gersh BJ, et al. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017;70(21):2621-32. DOI:10.1016/j.jacc.2017.09.1087.

52. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation. J Am Coll Cardiol. 2019;74(1):104-32. DOI:10.1016/j.jacc.2019.01.011.

53. Coleman CI, Kreutz R, Sood N, et al. Rivaroxaban’s Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis. Clin Appl Thromb Hemost. 2019;25:1076029619868535. DOI:10.1177/1076029619868535.

54. Chashkina MI, Andreev DA, Kozlovskaya NL, et al. Safety indicators of rivaroxaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Kardiologiia. 2020;60(11):94-100 (In Russ.) DOI:10.18087/cardio.2020.11.n1322.

55. Airy M, Schold JD, Jolly SE, et al. Cause-Specific Mortality in Patients with Chronic Kidney Disease and Atrial Fibrillation. Am J Nephrol. 2018;48(1):36–45. DOI:10.1159/000491023.

56. Mak KH. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open. 2012;2(5):e001592. DOI:10.1136/bmjopen-2012-001592.

57. Loke YK, Pradhan S, Yeong JK, Kwok CS. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol. 2014;78(4):707-17. DOI:10.1111/bcp.12376.

58. Chatterjee S, Sharma A, Uchino K, et al. Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials. Coron Artery Dis. 2013;24(8):628-35. DOI:10.1097/MCA.0000000000000031.

59. Halperin JL, Hankey GJ, Wojdyla DM, Jet al. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). 2014;130(2):138-46. DOI:10.1161/CIRCULATIONAHA.113.005008.

60. Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35(28):1864-72. DOI:10.1093/eurheartj/ehu046.

61. Coppens M, Eikelboom J, Ezekowitz M, et al. Dabigatran Versus Warfarin in Very Elderly Patients with Atrial Fibrillation: Results from the RE-LY Trial. Circulation. 2012;126 (suppl 21):A15537

62. Hanon O, Vidal JS, Pisica-Donose G, et al. Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation. Heart. 2021;107(17):1376-82. DOI:10.1136/heartjnl-2020-317923.

63. Bonnemeier H, Huelsebeck M, Kloss S. Comparative effectiveness of rivaroxaban versus a vitamin K antagonist in patients with renal impairment treated for non-valvular atrial fibrillation in Germany - A retrospective cohort study. Int J Cardiol Heart Vasc. 2019;23:100367. DOI:10.1016/j.ijcha.2019.100367.

64. Alberts M, Chen YW, Lin JH, et al. Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin. Stroke. 2020;51(2):549-55. DOI:10.1161/STROKEAHA.119.025554.

65. Factor XA – Inhibition in RENal Patients With Non-valvular Atrial Fibrillation – Observational Registry (XARENO) [cited 2021 Oct 10]. Available from:

66. Kachkovskiy МA, Krasnoslobodskaya OV. Adherence to drug therapy in patients with atrial fibrillation. RUDN Journal of Medicine. 2010;(4):229-33 (In Russ.)

67. Kwok CS, Loke YK, Hale R, et al. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology. 2011;76(10):914-22. DOI:10.1212/WNL.0b013e31820f2e38.

68. Santangeli P, Di Biase L, Bai R, et al. Atrial fibrillation and the risk of incident dementia: a meta-analysis. Heart Rhythm. 2012;9(11):1761-8. DOI:10.1016/j.hrthm.2012.07.026.

69. Alonso A, Knopman DS, Gottesman RF, et al. Correlates of Dementia and Mild Cognitive Impairment in Patients With Atrial Fibrillation: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). J Am Heart Assoc. 2017;6(7):e006014. DOI:10.1161/JAHA.117.006014.

70. Rivard L, Khairy P. Mechanisms, Clinical Significance, and Prevention of Cognitive Impairment in Patients With Atrial Fibrillation. Can J Cardiol. 2017;33(12):1556-1564. DOI:10.1016/j.cjca.2017.09.024.

71. Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment associated with atrial fibrillation: a meta-analysis. Ann Intern Med. 2013;158(5 Pt 1):338-46. DOI:10.7326/0003-4819-158-5-201303050-00007.

72. Kim D, Yang PS, Jang E, Yu HT, et al. Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation. Europace. 2021;23(2):184-95. DOI:10.1093/europace/euaa192.


For citation:

Pavlova T.V. Renal Function Protection as an Important Component of a Comprehensive Approach to the Management of Patients with Atrial Fibrillation. Rational Pharmacotherapy in Cardiology. 2021;17(6):916-926. (In Russ.)

Views: 57

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)